论文部分内容阅读
目的:评价佐芬普利钙片治疗原发性轻中度高血压的疗效和安全性。方法:采用随机双盲对照研究,设马来酸依那普利片为对照药物。随机入选病人共47例,佐芬普利组23例,依那普利组24例。两组分别服用佐芬普利15.0~30.0 mg和马来酸依那普利10.0~20.0 mg,两药用法均为每日1次,共8周。结果:与治疗前相比,治疗8周后佐芬普利组收缩压和舒张压分别下降6.72 mmHg和9.64 mmHg(P<0.05),依那普利组分别下降为5.03 mmHg和9.06 mmHg(P<0.05),均有统计学意义。佐芬普利组和依那普利组均无严重不良事件发生,佐芬普利组可能与药物相关的不良事件1例,依那普利组6例,有统计学差异(P<0.05)。结论:佐芬普利15~30 mg每日服用1次,可以显著地、平稳地降低血压,患者耐受性好。
Objective: To evaluate the efficacy and safety of zofenopril calcium in the treatment of primary mild to moderate hypertension. Methods: A randomized double-blind controlled study, enalapril maleate tablets as the control drug. A total of 47 patients were enrolled in the study, 23 in the zofenopril group and 24 in the enalapril group. Two groups were treated with zofenopril 15.0 ~ 30.0 mg and enalapril maleate 10.0 ~ 20.0 mg, two drugs were used daily for 8 weeks. RESULTS: After 8 weeks of treatment, systolic and diastolic blood pressure decreased 6.72 mmHg and 9.64 mmHg, respectively, in the zafinal group (5.03 mmHg vs 9.06 mmHg, P <0.05) <0.05), both of which have statistical significance. There were no serious adverse events in the zofenopril group and enalapril group, one case of possible drug-related adverse events in the zofenopril group and 6 cases in the enalapril group were statistically different (P <0.05) . Conclusion: Zofenopril 15 ~ 30 mg taken once daily can significantly and steadily lower blood pressure, and patients are well tolerated.